Daniel DeOliveira, PhD

Principal Consultant at Life Sciences Project Management

Speaker

Dr. Daniel B. DeOliveira has 20+ years of contributing to drug discovery and pharmaceutical science primarily in the areas of peptides & peptidomimetics, GMP Manufacturing and Technical Operations. He has led drug discovery efforts focusing on rare diseases, oncology, immune-oncology and nuclear medicine. He received his PhD in Medicinal Chemistry from Boston University. He went on to do initial immunology studies, at MIT, designing tight binding MHC antigens that could function as synthetic T-cell antigens. After several years at MIT, Dr. DeOliveira took a position in the private sector at Dyax Corp.

Dr. DeOliveira’s research while at Dyax contributed to the eventual FDA approval of Kalbitor (Ecallantide, DX-88) a treatment for hereditary angioedema. He then accepted an opportunity at Ipsen Bioscience with a focus on peptides as therapeutic drugs for rare diseases. While at Ipsen, he worked on several peptide-related programs including a Ghrelin agonist (Relamorelin™, BIM-28131) and a MC4R agonist (IMCIVREETM, Setmelanotide™, BIM-22943) which was recently approved for the treatment of POMC and LEPR Deficiency Obesities. He also led a nuclear medicine program aimed at targeting Neuroendocrine Tumors, where he developed a successful, novel approach to solve the kidney rate limiting effects of Peptide-Receptor Radio-Theranostics (PRRT) and successfully designed a peptide / small molecule combo to target Neuroendocrine tumors via a non-SSTR mechanism. He then went on Genocea Biosciences, again working on T-cell immunity, aiming to successfully develop peptide based neoantigen cancer vaccines for Genocea’s GEN-009 program as well as for GEN-011, an adoptive T-Cell therapy program, both of these programs are in clinical trials. He has served as VP of Technical Operations and Chemistry at Mytide Therapeutics, where he is working to bring autonomous manufacturing and machine learning into the world of peptide and oligo manufacturing to solve the molecular scarcity problem.